Home › NDC Lookup › Ingredients › Clotrimazole › 00574-0107-14
Clotrimazole 10 mg Lozenge, 140-count — NDC 00574-0107-14 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Clotrimazole 10 mg Lozenge, 140-count — NDC 0574-0107-14 (Billing 00574-0107-14)

by Padagis US LLC · 140 LOZENGE in 1 BOTTLE, PLASTIC

This is a package of 140 lozenges of Clotrimazole 10 mg Lozenge from Padagis US LLC, marketed since Dec 2005 and currently FDA-listed; retail pharmacies pay about $0.2923 per lozenge (NADAC).

NDC 00574-0107-14
🏷️ FDA NDC (as labeled) 0574-0107-14 billing pads the labeler segment with a zero
This package
Contains140-count Cost per ea$0.2923 NADAC Per package$40.92 / 140 lozenges Pack sizes3 compare ↓
Also priced by: Medicaid pays $0.4401/unit · Part D plans $0.5447/unit — full pricing hub ↓
Product page 00574-0107-70 Also comes in: 70 lozenges 0574-0107-70 70 lozenges 0574-0107-77
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0574-0107-14 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0574 labeler · 0107 product · 14 package
Package marketed since
Dec 1, 2005
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
140 EA per package
Barcode (UPC)
0305740107706
Medicaid fills, this package
536 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Clotrimazole (different manufacturers) — 2 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Oct 31, 2025 — cGMP deviations (Blossom Pharmaceuticals) · FDA recall D-0210-2026
Class II · Oct 31, 2025 — cGMP deviations (Blossom Pharmaceuticals) · FDA recall D-0211-2026
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0574-0107-14
Product NDC 0574-0107
11-digit billing NDC 00574010714
NCPDP billing unit EA — each (per item)
RxCUI 309371
UNII G07GZ97H65
UPC 0305740107706
Application # ANDA076763
SPL Set ID 3f57ef51-8202-4d0b-95a8-d2df468b8d9a
Established class (EPC) Azole Antifungal
Chemical class Azoles
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2005-12-01
Route ORAL
Dosage form LOZENGE
Substance CLOTRIMAZOLE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 88100020004805
GPI class Clotrimazole
GCN Seq No 009553
GCN 07590
HICL code 004137
Ingredient (HICL) Clotrimazole
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W3
Therapeutic class — intermediate (HIC2) Antimycotics
HIC3 code W3B
Therapeutic class — specific (HIC3) Antifungal Agents
AHFS code 84:04.08.08
AHFS class Azoles (Skin And Mucous Membrane)
FDB label name CLOTRIMAZOLE 10 MG TROCHE
FDB brand name Clotrimazole
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 009553
  • GCN: 07590
  • GPI-14 (Medi-Span): 88100020004805
  • HICL (First Databank): 004137
  • AHFS class code: 84:04.08.08
  • RxCUI (RxNorm): 309371
Why two NDCs? The FDA registers this code as 0574-0107-14 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00574-0107-14. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Azole Antifungal class.

Pharmacologic class Azole Antifungal
Drug family (ATC) Antiinfectives and antiseptics for local oral treatment, Imidazole and triazole derivatives, Imidazole derivatives
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name CLOTRIMAZOLE 10 MG TROCHE Ingredient Clotrimazole
📖 What it is MedlinePlus · NLM

Clotrimazole lozenges are used to treat yeast infections of the mouth in adults and children 3 years of age and older. It can also be used to prevent yeast infections of the mouth in people at risk of these infections who are receiving certain treatments. Clotrimazole is in a class of antifungal medications called imidazoles. It works by stopping the growth of fungi that cause infection.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats fungal and yeast infections. Skin products treat athlete's foot, jock itch and ringworm. Vaginal creams treat vaginal yeast infections, and CLOTIC ear solution treats fun...
  • Wash and dry the area, then apply a thin layer twice a day, morning and night. Most labels say about 4 weeks for athlete's foot and ringworm and 2 weeks for jock itch. See a doctor...
  • The skin products listed here say they are not effective on the scalp or nails. If the infection is there, check with your doctor.
  • With CLOTIC ear solution, the reported ones were headache, pain where it goes in, ringing in the ear and tingling. Vaginal cream can briefly increase burning or itching. Call your...
📖 Read our full Clotrimazole guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.292 $40.92 / 140 lozenges
Medicaid paysCMS SDUD · 12 mo $0.4401 $61.61 / 140 lozenges
Medicare drug plans payPart D · Q2 2026 $0.5447 $76.26 / 140 lozenges
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.456 $0.279
▼ Down 31% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00574-0107-14 You're viewing this 140 LOZENGE in 1 BOTTLE, PLASTIC $0.2923 / ea $40.92 2005-12-01 — Active
00574-0107-70 0574-0107-70 Main listing 70 LOZENGE in 1 BOTTLE, PLASTIC $0.2923 / ea $20.46 2005-12-01 — Active
00574-0107-77 0574-0107-77 70 PACKET in 1 BOX / 1 LOZENGE in 1 PACKET $0.3026 / ea $21.18 2005-12-01 — Active

This pack has the lowest per-ea cost of the 3 priced pack sizes ($0.2923 NADAC).

This pack accounts for about 4.7% of this product's recent Medicaid fills; most go to the 70 lozenges pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 140-count package — 140 lozenge in 1 bottle, plastic.
How does this package differ from NDC 00574-0107-70?
Both are Clotrimazole 10 mg Lozenge — the drug itself is identical. This page's package is the 140-count one, while NDC 00574-0107-70 is the 70 lozenges package.
What NDC number is used to bill for this package of Clotrimazole 10 mg Lozenge?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Clotrimazole 10 mg 00054-4146-22 Hikma 70 lozenges $0.292 AB Availability likely —
Clotrimazole 10 mgthis 00574-0107-14 Padagis 140 lozenges $0.292 AB Availability likely —
Clotrimazole 10 mg 16571-0686-07 Rising 70 lozenges $0.292 AB Availability likely —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2005
On the market since
Dec 2005
📍
2026
Currently FDA-listed
21 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
ImprintPAD;0107
Size16 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPadagis US LLC
Application holderPADAGIS US LLC
FDA applicationANDA076763 (ANDA)
Labeler code00574
First marketedDec 2005
Product typeHuman Prescription Drug
Portfolio63 products on file

More NDCs from Padagis US LLC labeler code 00574

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🧓 Geriatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description ⚠️ Precautions 🔒 Drug Abuse and Dependence 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 103 words ▾

INDICATIONS AND USAGE Clotrimazole lozenges are indicated for the local treatment of oropharyngeal candidiasis. The diagnoses should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole lozenges are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation.

There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .)

⏱️ Dosage and Administration 108 words ▾

DOSAGE AND ADMINISTRATION Clotrimazole lozenges must be slowly dissolved in the mouth. The recommended dose is one lozenge five times a day for fourteen consecutive days. Only limited data are available on the safety and effectiveness of the clotrimazole lozenge after prolonged administration; therefore, therapy should be limited to short term use, if possible.

For prophylaxis to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation, the recommended dose is one lozenge three times daily for the duration of chemotherapy or until steroids are reduced to maintenance levels.

⛔ Contraindications 15 words ▾

CONTRAINDICATIONS Clotrimazole lozenges are contraindicated in patients who are hypersensitive to any of its components.

⚠️ Warnings 15 words ▾

WARNING Clotrimazole lozenges are not indicated for the treatment of systemic mycoses including systemic candidiasis.

🤒 Adverse Reactions 49 words ▾

ADVERSE REACTIONS Abnormal liver function tests have been reported in patients treated with clotrimazole lozenges; elevated SGOT levels were reported in about 15% of patients in the clinical trials (See Precautions section). Nausea, vomiting, unpleasant mouth sensations and pruritus have also been reported with the use of the lozenge.

🤰 Pregnancy 168 words ▾

Usage in Pregnancy: Pregnancy Category C: Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity. The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180, and 100 times the human dose. Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning.

No effects were observed at 60 times the human dose. When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability. There are no adequate and well controlled studies in pregnant women.

Clotrimazole lozenges should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧒 Pediatric Use 45 words ▾

PEDIATRIC USE Safety and effectiveness of clotrimazole in children below the age of 3 years have not been established; therefore, its use in such patients is not recommended. The safety and efficacy of the prophylactic use of clotrimazole lozenges in children have not been established.

🧓 Geriatric Use 42 words ▾

GERIATRIC USE Clinical studies of clotrimazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

🆘 Overdosage 4 words ▾

OVERDOSAGE No data available.

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY Clotrimazole is a broad-spectrum antifungal agent that inhibits the growth of pathogenic yeasts by altering the permeability of cell membranes. The action of clotrimazole is fungistatic at concentrations of drug up to 20 mcg/mL and may be fungicidal in vitro against Candida albicans and other species of the genus Candida at higher concentrations. No single-step or multiple-step resistance to clotrimazole has developed during successive passages of Candida albicans in the laboratory; however, individual organism tolerance has been observed during successive passages in the laboratory.

Such in vitro tolerance has resolved once the organism has been removed from the antifungal environment. After oral administration of a 10 mg clotrimazole lozenge to healthy volunteers, concentrations sufficient to inhibit most species of Candida persist in saliva for up to three hours following the approximately 30 minutes needed for a lozenge to dissolve. The long term persistence of drug in saliva appears to be related to the slow release of clotrimazole from the oral mucosa to which the drug is apparently bound.

Repetitive dosing at three hour intervals maintains salivary levels above the minimum inhibitory concentrations of most strains of Candida; however, the relationship between in vitro susceptibility of pathogenic fungi to clotrimazole and prophylaxis or cure of infections in humans has not been established. In another study, the mean serum concentrations were 4.98 ± 3.7 and 3.23 ± 1.4 nanograms/mL of clotrimazole at 30 and 60 minutes, respectively, after administration as a lozenge.

📦 How Supplied / Storage and Handling 75 words ▾

HOW SUPPLIED Clotrimazole lozenges, 10 mg, white discoid, uncoated tablets, debossed with "PAD" over "0107" on one side and plain on the other, are supplied as follows: Strength NDC Code Lozenge Identification Bottles of 70: 10 mg 0574-0107-70 PAD 0107 Bottles of 140: 10 mg 0574-0107-14 PAD 0107 Boxes of 70 foil packs: 10 mg 0574-0107-77 PAD 0107 Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] Avoid freezing. Rx Only

📦 Storage and Handling 17 words ▾

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] Avoid freezing. Rx Only

📋 Description 58 words ▾

DESCRIPTION Each clotrimazole lozenge contains 10 mg clotrimazole [1-(o-chloro-α, α-diphenylbenzyl) imidazole], a synthetic antifungal agent, for topical use in the mouth. Structural Formula: Chemical Formula: C 22 H 17 ClN 2 The lozenge dosage form is a large, slowly dissolving tablet (troche) containing 10 mg of clotrimazole dispersed in dextrose, microcrystalline cellulose, povidone, and magnesium stearate. structural formula

⚠️ Precautions ~2 min read ▾

PRECAUTIONS Abnormal liver function tests have been reported in patients treated with clotrimazole lozenges; elevated SGOT levels were reported in about 15% of patients in the clinical trials. In most cases the elevations were minimal and it was often impossible to distinguish effects of clotrimazole from those of other therapy and the underlying disease (malignancy in most cases). Periodic assessment of hepatic function is advisable particularly in patients with pre-existing hepatic impairment.

Since patients must be instructed to allow each lozenge to dissolve slowly in the mouth in order to achieve maximum effect of the medication, they must be of such an age and physical and/or mental condition to comprehend such instructions. Carcinogenesis: An 18 month dosing study with clotrimazole in rats has not revealed any carcinogenic effect. Usage in Pregnancy: Pregnancy Category C: Clotrimazole has been shown to be embryotoxic in rats and mice when given in doses 100 times the adult human dose (in mg/kg), possibly secondary to maternal toxicity.

The drug was not teratogenic in mice, rabbits, and rats when given in doses up to 200, 180, and 100 times the human dose. Clotrimazole given orally to mice from nine weeks before mating through weaning at a dose 120 times the human dose was associated with impairment of mating, decreased number of viable young, and decreased survival to weaning. No effects were observed at 60 times the human dose.

When the drug was given to rats during a similar time period at 50 times the human dose, there was a slight decrease in the number of pups per litter and decreased pup viability. There are no adequate and well controlled studies in pregnant women. Clotrimazole lozenges should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE Safety and effectiveness of clotrimazole in children below the age of 3 years have not been established; therefore, its use in such patients is not recommended. The safety and efficacy of the prophylactic use of clotrimazole lozenges in children have not been established. GERIATRIC USE Clinical studies of clotrimazole did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

🔒 Drug Abuse and Dependence 7 words ▾

DRUG ABUSE AND DEPENDENCE No data available.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 16 words ▾

Carcinogenesis: An 18 month dosing study with clotrimazole in rats has not revealed any carcinogenic effect.

📄 Package Label / Principal Display Panel 88 words ▾

PRINCIPAL DISPLAY PANEL NDC 0574-0107-70 Rx Only Clotrimazole Lozenge (Clotrimazole Troche) 10 mg DESCRIPTION: Each lozenge contains 10 mg of clotrimazole, [1-(ο-chloro-α,α-diphenylbenzyl)imidazole]. DOSAGE: Each lozenge must be dissolved slowly in the mouth. See accompanying literature for complete information.

Dispense in tight containers (USP). Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] Avoid freezing. 70 Lozenges The following image is a placeholder representing the product identifier that is either affixed or imprinted on the drug package label during the packaging operation. label image serialization-template

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
536
Units reimbursed last 4 qtrs
33K
Gross reimbursed last 4 qtrs
$14.5K
Avg / prescription
$27.08
Avg / unit
$0.4401
Latest quarter Q1 2026
142Rx
Medicaid pays / ea
$0.4401
gross reimbursed
vs
NADAC / ea
$0.2923
acquisition cost
=
Spread
+$0.1478
+51% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
35% FFS 65% MCO
Fee-for-service · 189 Rx Managed care · 347 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: 8,462 units · 108 per 100k residents WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 875 units · 14.8 per 100k residents WI Michigan: no data reported MI New York: 7,583 units · 38.7 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 2,133 units · 50.4 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 905 units · 7.2 per 100k residents IL Indiana: no data reported IN Ohio: no data reported OH Pennsylvania: 7,064 units · 54.5 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: 4,317 units · 11.1 per 100k residents CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 733 units · 16.2 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 911 units · 14.7 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
7.2108
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Washington 108 /100k
2 Pennsylvania 54.5 /100k
3 Oregon 50.4 /100k
4 New York 38.7 /100k
5 Kentucky 16.2 /100k
6 Wisconsin 14.8 /100k
7 Maryland 14.7 /100k
8 California 11.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
70 lozenges00574-0107-70 10,907 Rx · $292,685
140 lozenges this page00574-0107-14 536 Rx · $14,517
70 lozenges00574-0107-77 No Medicaid data
Drug total (last 4 qtrs): 11,443 Rx · 618,182 units · $307,202 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Clotrimazole — the program that covers self-administered drugs. 13 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Clotrimazole. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$6.43M
Claims incl. refills
276K
Beneficiaries
207.9K
Spend / beneficiary
$30.91
Spend / claim
$23.28
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00574-0106-01 · Padagis 00574-0115-01 · Padagis →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.